KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 44, Issue 2, 2009, Pages 97-103

  Ludajic, K ^a   Balavarca, Y ^b   Bickeboller H ^b   Rosenmayr, A ^a   Fae, I ^a   Fischer, G F ^a   Kouba, M ^a   Pohlreich, D ^a   Kalhs, P ^a   Greinix, H T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOSS; GENETIC ASSOCIATION; GENOTYPE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLELES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LIGANDS; LIVING DONORS; MALE; MIDDLE AGED; RECEPTORS, KIR; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 68149164836     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.432     Document Type: Article

References (38)

1. Uhrberg M, Valiante NM, Young NT, Lanier LL, Phillips JH, Parham P. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: Clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns. J Immunol 2001; 166: 3923-3932.
2. Flores AC, Marcos CY, Paladino N, Capucchio M, Theiler G, Arruvito L et al. KIR genes polymorphism in Argentinean Caucasoid and Amerindian populations. Tissue Antigens 2007; 69: 568-576.
3. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: Evidence for genomic diversity witha minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002; 169: 5118-5129.
4. Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 2002; 54: 221-229.
5. Velickovic M, Velickovic Z, Dunckley H. Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations. Immunogenetics 2006; 58: 523-532.
6. Single RM, Martin MP, Gao X, Meyer D, Yeager M, Kidd JR et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007; 39: 1114-1119.
7. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214.
8. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
10. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
11. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007; 97: 539-542.
12. Witt CS, Christiansen FT. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang 2006; 90: 10-20.
13. Fischer JC, Ottinger H, Ferencik S, Sribar M, Punzel M, Beelen DW et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: Role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol 2007; 178: 3918-3923.
14. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-1526.
15. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007; 68: 309-323.
16. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249-257.
17. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
18. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864.
19. Fischer GF, Fae I, Frey E, Mayr WR. HLA-A*02172* adds to the heterogeneity of HLA-A*02 alleles. Tissue Antigens 1998; 51 312-314.
20. Du Z, Gjertson DW, Reed EF, Rajalingam R. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics 2007; 59: 1-15.
21. Atkinson EJ, Therneau TM. An Introduction to Recursive Partitioning using the RPART Routines, vol. 61 Mayo Clinic: Rochester, 1997.
22. Breiman L, Friedman JH, Stone CJ, Olshen RA. Classification and Regression Trees, 1 edn. Chapman & Hall/CRC: London, 1984.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 1999; 94: 496-509.
24. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451.
25. Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates withHLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 2007; 39: 417-424.
26. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-5061.
27. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38: 437-444.
28. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148: 520-528.
29. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-280.
30. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39: 733-740.
31. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al. Donors withgroup B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; e-pub ahead of print, 22 October 2008; doi:10.1182/blood-2008-07-171926.
32. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
33. Sun JY, Dagis A, Gaidulis L, Miller MM, Rodriguez R, Parker P et al. Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients. Biol Blood Marrow Transplant 2007; 13: 197-205.
34. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
35. Guerra N, Michel F, Gati A, Gaudin C, Mishal Z, Escudier B et al. Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood 2002; 100: 2874-2881.
36. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
37. Junevik K, Werlenius O, Hasselblom S, Jacobsson S, Nilsson-Ehle H, Andersson PO. The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL). Ann Hematol 2007; 86: 89-94.
38. Poon K, Montamat-Sicotte D, Cumberbatch N, McMichael AJ, Callan MF. Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo. Viral Immunol 2005; 18: 513-522.